Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.


Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?


Please Try Again {{ error }}

Send my password

An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Opinion & Analysis Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral develops devices for unmet medical needs. Sepsis occurs in 1.7M Americans/year causing 250K deaths, often caused by endotoxin. Our devices measure and remove endotoxin from the bloodstream. An FDA confirmatory trial is underway. Dialco, a Spectral sub, offers SAMI, a novel instrument for renal replacement, cleared by FDA. Dialco is seeking FDA approval for DIMI a unique home dialysis enabler. These devices have large commercial potential

Opinion & Analysis (TSX:EDT)

    Buzz on the Bullboards: Eye of the Storm

    Omri Wallach November 14, 2019

    Blogger wonders if now is the right time to buy Keek (V.KEK)

    Stockhouse Editorial June 25, 2015

    My venture basket of juniors is updated, Stockhouse blogger says

    Stockhouse Editorial June 24, 2015

    Canadian Biotech comes back to life: A buyer's guide

    Tony Pullen January 21, 2014

    Mystery Movers: Biomed shares surging, triple digit rises all over, executives baffled

    Chris Parry November 19, 2013

    Mystery Movers: Spectral Diagnostics jumps 22% as Canadian biotech goes viral

    Chris Parry November 5, 2013

    Rare earth junior could have another good year ... or two

    Danny Deadlock February 7, 2011

    Not All Swell At Medwell

    Danny Deadlock December 16, 2010

    Venture Exchange move creates bottom fishing opportunity:

    Danny Deadlock September 8, 2010

    Biotech may have been overlooked:

    Danny Deadlock August 16, 2010

    Biotech could get a big investment boost:

    Danny Deadlock June 28, 2010

    The liquidation equation: The StreetSignal Report

    Danny Deadlock April 12, 2010

    Value updates for biotech and junior gold companies: The StreetSignal Report

    Danny Deadlock March 22, 2010

    Biotech investment offers cash rich value plus investment: The StreetSignal Report

    Danny Deadlock March 1, 2010

    Our top biotech, gold, and tech stock picks for 2010

    Danny Deadlock January 4, 2010